siRNA PLK1-LNPs achieved significant PLK1 gene silencing by more than 2-fold and improved cell targeting by 1.2 to over 4.5 times in EGFR+ high-risk neuroblastoma cells. This evidence concerns the gene EGFR and neuroblastoma.